Clinical trials: REE
Multiple Sclerosis
Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome
Multiple sclerosis (MS) is a common cause of severe neurological disability in young adults, resulting from an autoimmune interruption of both myelin and axons within the central nervous system (CNS).
- Trial name
- TERIS (NCT03122652)
- Testing
- Teriflunomide 14 MG Oral Tablet [Aubagio]
- Where
- 23 sites in France, Switzerland and 1 more
- Volunteers
- 125 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Primary Osteoporosis
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by oral administration every day.
- Trial name
- NCT00447915
- Testing
- ibandronic acid 0.5mg, 1.0mg ibandronic acid, 2.5mg RIS
- Where
- 4 sites in Japan
- Volunteers
- 1,265 people
- Sponsor
- Chugai Pharmaceutical
Neoplasms
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227.
- Trial name
- PanTumor-101 (NCT06551142)
- Testing
- Ris-Rez, Cisplatin, Carboplatin
- Where
- 67 sites in United States, Argentina and 11 more
- Volunteers
- 845 people
- Sponsor
- GlaxoSmithKline